Active substanceCalcium gluconateCalcium gluconate
Similar drugsTo uncover
  • Calcium gluconate
    pills inwards 
    ATOLL, LLC     Russia
  • Calcium gluconate
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    pills inwards 
  • Calcium gluconate
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Calcium gluconate
    pills inwards 
  • Calcium gluconate
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Calcium gluconate
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Calcium gluconate
    solution w / m in / in 
    BINNOFARM, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
    TRIM, LLC     Russia
  • Calcium gluconate
    pills inwards 
    LYUMI, LLC     Russia
  • Calcium gluconate
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
    DALHIMFARM, OJSC     Russia
  • Calcium gluconate
    pills inwards 
    MEDISORB, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    solution w / m in / in 
    ESKOM NPK, OAO     Russia
  • Calcium gluconate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Calcium gluconate, stabilized
    solution for injections 
    FARMAK, PAO     Ukraine
  • Calcium gluconate, stabilized
    solution w / m in / in 
  • Calcium gluconate Extrabate
    pills inwards 
  • Calcium gluconate-Vial
    solution w / m in / in 
    VIAL, LLC     Russia
  • Calcium gluconate-lekT
    pills inwards 
  • Calcium gluconate-SOLOfarm
    solution w / m in / in 
    GROTEKS, LLC     Russia
  • Dosage form: & nbspchewing tablets
    Composition:

    Each tablet contains:

    active substance: calcium gluconate monohydrate - 500 mg;

    Excipients: lactose monohydrate, lactitol, kenlitol, sodium cyclamate, orange or mint flavor, or apple, magnesium stearate.

    Description:

    Tablets are white or almost white, round, flat-cylindrical with a facet and a risk, with a characteristic weak orange or mint, or apple smell.

    Pharmacotherapeutic group:Calcium-phosphorus exchange regulator
    ATX: & nbsp

    A.12.A.A.03   Calcium gluconate

    A.12.A.A   Calcium preparations

    Pharmacodynamics:

    The source of calcium ions, refers to the means regulating metabolic processes. Replenishes the deficiency of calcium, necessary for the process of transmission of nerve impulses, reduction of skeletal and smooth muscles, contractility of the myocardium, formation of bone tissue, clotting of blood.

    In addition, it has anti-allergic and anti-inflammatory effects.
    Pharmacokinetics:

    After oral administration, about 30% of ionized calcium is absorbed in the gastrointestinal tract; this process depends on the presence of the vitamin D, pH, dietary characteristics and the presence of factors that are able to bind calcium. The absorption of calcium increases with its deficiency and the use of a diet with a reduced content of calcium. After oral administration, the maximum concentration in the blood plasma is reached after 1.2-1.3 hours. It penetrates through the placental barrier, is excreted in breast milk.

    About 20% is excreted by the kidneys, the remaining amount (80%) is removed from the intestinal contents (actively allocated by the wall of the terminal section of the gastrointestinal tract).

    Indications:
    • Diseases accompanied by hypocalcemia, increased permeability of cell membranes (incl.vessels), a violation of the conduction of nerve impulses in the muscle tissue.
    • Hypoparathyroidism (latent tetany, osteoporosis), metabolic disturbances of vitamin D: rickets (spasmophilia, osteomalacia), hyperphosphataemia in patients with chronic renal insufficiency.
    • The increased need for calcine (pregnancy, lactation, a period of increased body growth), insufficient calcium in food, a violation of its metabolism (in the postmenopausal period).
    • Enhanced excretion of calcium (prolonged bed rest, chronic diarrhea, secondary hypocalcemia, long-term use of diuretics and antiepileptic drugs, glucocorticosteroids).
    • Bleeding, which does not require parenteral administration of drugs (as part of complex therapy); allergic diseases (serum sickness, urticaria, febrile syndrome, itching, itching dermatoses, reactions to the administration of medicines and food intake, bronchial asthma) as part of complex therapy; dystrophic alimentary swelling, pulmonary tuberculosis, lead colic; prevention of eclampsia.
    • Poisoning with magnesium salts, oxalic and fluoric acids and their soluble salts (in the interaction with calcium gluconate insoluble and non-toxic calcium oxalate and calcium fluoride are formed).
    • Parenchymal hepatitis, toxic liver damage, nephritis, hyperkalemic form of proximal myoplegia.
    Contraindications:

    Increased individual sensitivity to one of the components of the drug, hypercalcemia (calcium concentration should not exceed 12 mg% = 6 mEq / L), expressed hypercalciuria, nephrourolythiasis (calcium), sarcoidosis, simultaneous reception of cardiac glycosides (risk of arrhythmias), children under 3 years.

    Carefully:

    Dehydration, electrolyte disorders (risk of hypercalcemia), diarrhea, malabsorption syndrome, calcium nephrourolythiasis (in the anamnesis), minor hypercalciuria, moderate CRF, CHF, prevalent atherosclerosis, hypercoagulation.

    Dosing and Administration:

    Inside, before meals or 1-1.5 hours after eating. Before swallowing, the tablets are chewed, washed down with a small amount of water or milk. ATadult - 1-3 g 2-3 times a day.

    Children 3-4 years - 1 g; 5-6 years - 1-1.5 g; 7-9 years - 1.5-2 g; 10-14 years - 2-3 g; the frequency of reception is 2-3 times a day.

    Side effects:

    With prolonged use of calcium gluconate, constipation, irritation of the mucous membrane of the gastrointestinal tract, and sometimes the formation of calcified stones in the intestine.

    Overdose:

    Excessive long-term use of calcium preparations can lead to hypercalcemia with the deposition of calcium salts in organs and vessels.

    Symptoms of overdose: drowsiness, weakness, anorexia, nausea, vomiting, constipation, polyuria, dehydration, cardiac rhythm disturbances are possible.

    Treatment: Antidote is used calcitonin iv in the calculation of 5-10 IU / kg (diluting it in 500 ml of 0.9% sodium chloride solution). Duration of administration 6 hours.

    Interaction:

    Forms insoluble or hardly soluble calcium salts with carbonates, salicylates, sulfates.

    Reduces the antibacterial effect of tetracycline antibiotics, forming insoluble complexes with them.

    With simultaneous application with quinidine, it is possible to slow intraventricular conduction and increase the toxicity of quinidine.

    Slows down the absorption of tetracyclines, digoxin.oral iron preparations (the interval between their methods should be at least 2 hours).

    When combined with thiazide diuretics can increase hypercalcemia, reduce the effect of calcitonin in hypercalcemia. reduces the bioavailability of phenytoin.

    Special instructions:

    Patients with minor hypercalciuria, reduced glomerular filtration or with nephrourolythiasis in history should be administered under the control of the concentration of calcium in the urine.

    Drinking plenty is recommended to reduce the risk of nephrourolythiasis.

    Form release / dosage:Chewable tablets (orange, mint, apple) 500 mg.
    Packaging:

    For 4, 6 or 10 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil printed lacquered.

    By 1, 2, 3, 4, 5 contour packs with instructions for use in a pack of cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-000287/10
    Date of registration:25.01.2010 / 11.05.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp23.11.2017
    Illustrated instructions
      Instructions
      Up